Comparative Pharmacology
Head-to-head clinical analysis: APRESOLINE ESIDRIX versus EUTRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APRESOLINE ESIDRIX versus EUTRON.
APRESOLINE-ESIDRIX vs EUTRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apresoline (hydralazine) is a direct-acting vasodilator that relaxes arteriolar smooth muscle via unknown mechanism; Esidrix (hydrochlorothiazide) is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule.
EUTRON is a combination of hydrochlorothiazide (thiazide diuretic) and pargyline (monoamine oxidase inhibitor, MAOI). Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, reducing plasma volume. Pargyline inhibits MAO, increasing catecholamine levels centrally, leading to antihypertensive effect.
Hydralazine (Apresoline): Oral, initial 10 mg 4 times daily for first 2-4 days, then increase to 25 mg 4 times daily for first week, then 50 mg 4 times daily thereafter. Maximum daily dose: 300 mg. Hydrochlorothiazide (Esidrix): Oral, initial 12.5-25 mg once daily, may increase to 50 mg once daily if needed.
Oral: 5 mg/2.5 mg (amiodipine/valsartan) once daily; maximum dose 10 mg/320 mg once daily.
None Documented
None Documented
Hydralazine: 2-8 h (prolonged in renal impairment); Hydrochlorothiazide: 6-15 h (mean 10 h, increased in renal failure).
Terminal elimination half-life is 12-15 hours in patients with normal renal function. In end-stage renal disease (ESRD), half-life may extend to 24-30 hours, requiring dose adjustment.
Renal: Hydralazine 85-90% as metabolites, 5-10% unchanged; Hydrochlorothiazide 95% as unchanged drug. Biliary/fecal: Hydralazine <10%.
Renal excretion accounts for approximately 90% of elimination, with 70% as unchanged drug and 20% as metabolites. Biliary/fecal excretion accounts for the remaining 10%.
Category C
Category C
Antihypertensive
Antihypertensive